



BioMmune Announces Results of Initial UBC Work Program

Vancouver, British Columbia, March 3rd, 2014 - BioMmune Technologies Inc., (TSX.V:IMU) a company focused on harnessing the body's own immune system to fight cancer and other autoimmune diseases, has received initial results from The University of British Columbia ("UBC") screening program.

One of the three key programs BioMmune is currently working on at UBC is a complex screening program on a marine extract library of compounds provided by Dr. Raymond Andersen UBC, Professor of Chemistry, Department of Earth, Ocean & Atmospheric Sciences and his colleagues. This library has previously yielded important new small molecule drugs. As cancer cells transition from primary to metastatic they continue to evolve under the negative selection of the immune system until the cancer cell learn to hide from the human immune system. The screen devised and developed at UBC by Professor Wilfred Jefferies and his colleagues in UBC's, Michael Smith Laboratory, identifies small molecules that unmask the metastatic forms of cancer and re-enables the body's own immune system to attack the cancer cells.

"The development of cancer therapeutics has evolved significantly due to the ability to diagnose cancer much earlier than in the past. Early cancer therapeutics were for the most part, indiscriminate and simply targeted dividing cells and thereby killing both normal and cancerous cells. Today a more deeper understanding of the processes leading to the emergence of cancers have led to the development of better biologics that focus on only selectively killing cancer cells and rendering normal cells and tissues unharmed. The human body possesses an immune mechanism, that already recognizes abnormal cells from normal cells and eliminates abnormal cells, but during the course of cancer, the cancer cells can develop an ingenious strategy to hide from the immune system. The approach we have taken, is to unmask and restore selective cancer recognition by the immune system. This development project is now well advanced and provides the promise of a new class of anti-cancer drugs," says Dr. Reinhard Gabathuler, President of BioMmune.

"We are very pleased and excited with the initial results from the screening program. Thus far, UBC has examined hundreds of natural marine product extracts that are known to be rich in new drug candidates. Five of these extracts contain compounds that show promising activity in the screen," said Dr. Gabathuler. "Furthermore, in several cases, we have identified the unique chemical structures of potential drug leads and are in the process of protecting intellectual property related to these new chemical entities. Thus, we anticipate the development of a number of new and proprietary anti-cancer therapeutics resulting from this program that may provide treatments for aggressive malignancies such as breast, prostate, colorectal and pancreatic cancers, as well as lymphomas and lung carcinomas and skin melanomas. Our additional programs on the development of new vaccine technologies and the program for creating biologics to treat autoimmune diseases are also advancing."

ABOUT BIOMMUNE

BioMmune Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. BioMmune is developing three technologies discovered at The University of British Columbia. They include, discovery of compounds that will be active in restoring immune-recognition of cancer cells resulting in the body's immune system to fight the cancer cells. A discovery relating to Calcium Channels, whose activities regulate the concentration of calcium (Ca) in different compartments in cells, which is very important for the activity of cells involved in the immune system to improve their ability to combat cancers, infections and also autoimmunities. Furthermore, the company is pursuing the modulation of CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding ways or compounds that regulate its activity will improve the immune system to combat infections, cancers and autoimmune diseases. BioMmune trades on the TSX Venture Exchange under the symbol "IMU".

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be successful in either preclinical or clinical trials and not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Reinhard Gabathuler, President
(604)644.1232
gaba@biommune.net

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"